BACKGROUND: We evaluated which patient factors were associated with treatment tolerance and outcome in elderly colon cancer patients. DESIGN: Population-based data from five regions included in the Netherlands Cancer Registry were used. Patients with resected stage III colon cancer aged ≥75 years diagnosed in 1997-2004 who received adjuvant chemotherapy (N = 216) were included as well as a random sample (N = 341) of patients who only underwent surgery. RESULTS: The most common motives for withholding adjuvant chemotherapy were a combination of high age, co-morbidity and poor performance status (PS, 43%) or refusal by the patient or family (17%). In 57% of patients receiving chemotherapy, adaptations were made in treatment regimens. Patients who received adjuvant chemotherapy developed more complications (52%) than those with surgery alone (41%). For the selection of patients who had survived the first year after surgery, receiving adjuvant chemotherapy resulted in better 5-year overall survival (52% versus 34%), even after adjustment for differences in age, co-morbidity and PS. CONCLUSION: Despite high toxicity rates and adjustments in treatment regimens, elderly patients who received chemotherapy seemed to have a better survival. Prospective studies are needed for evaluating which patient characteristics predict the risks and benefits of adjuvant chemotherapy in elderly colon cancer patients.
BACKGROUND: We evaluated which patient factors were associated with treatment tolerance and outcome in elderly colon cancerpatients. DESIGN: Population-based data from five regions included in the Netherlands Cancer Registry were used. Patients with resected stage III colon cancer aged ≥75 years diagnosed in 1997-2004 who received adjuvant chemotherapy (N = 216) were included as well as a random sample (N = 341) of patients who only underwent surgery. RESULTS: The most common motives for withholding adjuvant chemotherapy were a combination of high age, co-morbidity and poor performance status (PS, 43%) or refusal by the patient or family (17%). In 57% of patients receiving chemotherapy, adaptations were made in treatment regimens. Patients who received adjuvant chemotherapy developed more complications (52%) than those with surgery alone (41%). For the selection of patients who had survived the first year after surgery, receiving adjuvant chemotherapy resulted in better 5-year overall survival (52% versus 34%), even after adjustment for differences in age, co-morbidity and PS. CONCLUSION: Despite high toxicity rates and adjustments in treatment regimens, elderly patients who received chemotherapy seemed to have a better survival. Prospective studies are needed for evaluating which patient characteristics predict the risks and benefits of adjuvant chemotherapy in elderly colon cancerpatients.
Authors: Anne Benard; Eliane C M Zeestraten; Inès J Goossens-Beumer; Hein Putter; Cornelis J H van de Velde; Dave S B Hoon; Peter J K Kuppen Journal: Apoptosis Date: 2014-11 Impact factor: 4.677
Authors: Re-I Chin; Kevin Chen; Abul Usmani; Chanelle Chua; Peter K Harris; Michael S Binkley; Tej D Azad; Jonathan C Dudley; Aadel A Chaudhuri Journal: Mol Diagn Ther Date: 2019-06 Impact factor: 4.074
Authors: Nina C A Vermeer; Yvette H M Claassen; Marloes G M Derks; Lene H Iversen; Elizabeth van Eycken; Marianne G Guren; Pawel Mroczkowski; Anna Martling; Robert Johansson; Tamara Vandendael; Arne Wibe; Bjorn Moller; Hans Lippert; Johanneke E A Portielje; Gerrit Jan Liefers; Koen C M J Peeters; Cornelis J H van de Velde; Esther Bastiaannet Journal: Oncologist Date: 2018-03-22
Authors: Melissa J J Voorn; Bart C Bongers; Vivian E M van Kampen-van den Boogaart; Elisabeth J M Driessen; Maryska L G Janssen-Heijnen Journal: Cancers (Basel) Date: 2022-05-12 Impact factor: 6.575
Authors: Nadine J McCleary; Sui Zhang; Chao Ma; Fang-Shu Ou; Tiffany M Bainter; Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Bert H O'Neil; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Kimmie Ng; Robert J Mayer; Charles D Blanke; Eileen M O'Reilly; Charles S Fuchs; Jeffrey A Meyerhardt Journal: J Geriatr Oncol Date: 2022-01-31 Impact factor: 3.929
Authors: Anne Benard; Inès J Goossens-Beumer; Anneke Q van Hoesel; Hamed Horati; Hein Putter; Eliane C M Zeestraten; Cornelis J H van de Velde; Peter J K Kuppen Journal: PLoS One Date: 2014-09-22 Impact factor: 3.240
Authors: Zeta Chow; Tong Gan; Quan Chen; Bin Huang; Nancy Schoenberg; Mark Dignan; B Mark Evers; Avinash S Bhakta Journal: J Am Coll Surg Date: 2020-02-13 Impact factor: 6.532